Enliven Therapeutics Inc (ELVN)
20.47
-1.09
(-5.06%)
USD |
NASDAQ |
Jun 18, 16:00
21.20
+0.73
(+3.57%)
Pre-Market: 20:00
Enliven Therapeutics Enterprise Value: 642.34M for June 18, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 18, 2024 | 642.34M |
| June 17, 2024 | 693.61M |
| June 14, 2024 | 700.19M |
| June 13, 2024 | 715.24M |
| June 12, 2024 | 749.58M |
| June 11, 2024 | 713.83M |
| June 10, 2024 | 741.58M |
| June 07, 2024 | 664.44M |
| June 06, 2024 | 629.64M |
| June 05, 2024 | 640.93M |
| June 04, 2024 | 663.97M |
| June 03, 2024 | 670.09M |
| May 31, 2024 | 741.11M |
| May 30, 2024 | 739.70M |
| May 29, 2024 | 682.79M |
| May 28, 2024 | 771.69M |
| May 24, 2024 | 805.55M |
| May 23, 2024 | 760.40M |
| May 22, 2024 | 756.17M |
| May 21, 2024 | 756.64M |
| May 20, 2024 | 808.38M |
| May 17, 2024 | 763.22M |
| May 16, 2024 | 799.44M |
| May 15, 2024 | 808.38M |
| May 14, 2024 | 802.26M |
| Date | Value |
|---|---|
| May 13, 2024 | 831.42M |
| May 10, 2024 | 781.57M |
| May 09, 2024 | 803.67M |
| May 08, 2024 | 831.42M |
| May 07, 2024 | 841.30M |
| May 06, 2024 | 757.58M |
| May 03, 2024 | 744.88M |
| May 02, 2024 | 666.80M |
| May 01, 2024 | 530.86M |
| April 30, 2024 | 496.92M |
| April 29, 2024 | 515.72M |
| April 26, 2024 | 487.05M |
| April 25, 2024 | 468.25M |
| April 24, 2024 | 501.62M |
| April 23, 2024 | 495.98M |
| April 22, 2024 | 507.73M |
| April 19, 2024 | 491.75M |
| April 18, 2024 | 506.55M |
| April 17, 2024 | 489.23M |
| April 16, 2024 | 554.29M |
| April 15, 2024 | 612.80M |
| April 12, 2024 | 666.15M |
| April 11, 2024 | 794.40M |
| April 10, 2024 | 607.18M |
| April 09, 2024 | 577.69M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
154.00M
Minimum
Dec 12 2023
907.51M
Maximum
Mar 29 2023
474.70M
Average
468.25M
Median
Apr 25 2024
Enterprise Value Benchmarks
| Eyenovia Inc | 41.05M |
| Phathom Pharmaceuticals Inc | 521.61M |
| Lantern Pharma Inc | 12.10M |
| Vincerx Pharma Inc | 12.61M |
| NKGen Biotech Inc | 51.29M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -22.74M |
| Total Expenses (Quarterly) | 25.99M |
| EPS Diluted (Quarterly) | -0.54 |
| Earnings Yield | -9.38% |